ChemIDplus Advanced United States National Library of Medicine Accessed on 29 Jul 2013 from http://chem.sis.nlm.nih.gov/chemidplus/chemidheavy.jsp. Note: Compound name must be entered under "Substance Identification" and then "Names and Synonyms" selected to view synonyms.
Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine. Warnke C, Wiendl H, Hartung H-P, Stüve O, Kieseier BC Drug Des Devel Ther. 2010; 4:117-26. Epub 2010 Jul 21. PMID: 20689698. Abstract
Merck: Regulatory Update on Cladribine Tablets The Merck Group, 22 Jun 2011 Accessed on 20 Feb 2012 from http://www.merckgroup.com/en/media/extNewsDetail.html?newsId=DAA395BF12E226E6C12578B6007430DB&newsType=1.
Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis. Murphy JA, Harris JA, Crannage AJ Neuropsychiatr Dis Treat. 2010; 6:619-25. Epub 2010 Oct 05. PMID: 20957121. Abstract
Development of cladribine at Scripps for hairy cell leukemia and current results. Torrey ML, Sigal DS, Saven A Leuk Lymphoma. 2011 Jun; 52 Suppl 2:29-33. Epub 2011 Apr 19. PMID: 21504293. Abstract
Clarity Extension Study ClinicalTrials.gov, 23 Jan 2012 Accessed on 20 Feb 2012 from http://clinicaltrials.gov/ct2/show/NCT00641537?term=MS+CLARITY&rank=2.
Oracle Cladribine in Early Multiple Sclerisis (MS) (ORACLE MS) ClinicalTrials.gov, 28 Sep 2011 Accessed on 20 Feb 2012 from http://clinicaltrials.gov/ct2/show/NCT00725985?term=MS+ORACLE&rank=1.
EMD Serono EMD Serono, 9 Feb 2012 Accessed on 20 Feb 2012 from http://www.emdserono.com/en/index.html;jsessionid=E5D1C8EE0936FF1B3BCDDCF774D66986.
CLARITY – Safety and Efficacy of Oral Cladribine in Subjects with Relapsing-remitting Multiple Sclerosis (MS) ClinicalTrials.gov, 27 Jan 2012 Accessed on 20 Feb 2012 from http://clinicaltrials.gov/ct2/show/NCT00213135.
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials ClinicalTrials.gov, 22 Jul 2011 Accessed on 20 Feb 2012 from http://clinicaltrials.gov/ct2/show/NCT01013350?term=cladribine&rank=24.
Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Carson DA, Wasson DB, Taetle R, Yu A Blood. 1983 Oct; 62(4):737-43. PMID: 6136305. Abstract
Cladribine Drugs.com, Jan 2012 Accessed on 20 Feb 2012 from http://www.drugs.com/pro/cladribine.html.
Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis. Kopadze T, Döbert M, Leussink VI, Dehmel T, Kieseier BC Eur J Neurol. 2009 Mar; 16(3):409-12. PMID: 19175384. Abstract
Impact of cladribine on soluble adhesion molecules in multiple sclerosis. Mitosek-Szewczyk K, Stelmasiak Z, Bartosik-Psujek H, Belniak E Acta Neurol Scand. 2010 Dec; 122(6):409-13. PMID: 20175758. Abstract
Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis. Janiec K, Wajgt A, Kondera-Anasz Z Med Sci Monit. 2001 Jan-Feb; 7(1):93-8. PMID: 11208501. Abstract
Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine. Bartosik-Psujek H, Belniak E, Mitosek-Szewczyk K, Dobosz B, Stelmasiak Z Acta Neurol Scand. 2004 Jun; 109(6):390-2. PMID: 15147461. Abstract
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Sørensen P S, Vermersch P, Chang P, Hamlett A, Musch B, et al. N Engl J Med. 2010 Feb 4; 362(5):416-26. Epub 2010 Jan 20. PMID: 20089960. Abstract
Phase II Cladribine Add-on to Interferon-beta (IFN-b) Therapy in MS Subjecs With Active Disease (ONWARD) ClinicalTrials.gov, 19 Jan 2012 Accessed on 20 Feb 2012 from http://clinicaltrials.gov/ct2/show/NCT00436826?term=cladribine+multiple+sclerosis&rank=2.
Effects of 2-Chlorodeoxyadenosine (Cladribine) on Primary Rat Microglia. Singh V, Voss E V, Bénardais K, Stangel M J Neuroimmune Pharmacol. 2012 Jul 21. Epub 2012 Jul 21. PMID: 22821377. Abstract
Chronic cladribine administration increases amyloid Beta Peptide generation and plaque burden in mice. Hayes CD, Dey D, Palavicini J P, Wang H, Araki W, Lakshmana MK PLoS One. 2012; 7(10):e45841. Epub 2012 Oct 03. PMID: 23056220. Abstract
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. Comi G, Cook SD, Giovannoni G, Rammohan K, Rieckmann P, Sørensen P S, Vermersch P, Hamlett AC, Viglietta V, Greenberg SJ J Neurol. 2012 Dec 21. Epub 2012 Dec 21. PMID: 23263473. Abstract
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P, Sørensen SP, Hamlett A, Miret M, Weiner J, et al. Mult Scler. 2011 May; 17(5):578-93. Epub 2011 Jan 12. PMID: 21228029. Abstract
Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study. Ali S, Paracha N, Cook S, Giovannoni G, Comi G, Rammohan K, Rieckmann P, Sørensen P S, Vermersch P, Greenberg S, et al. Clin Drug Investig. 2012 Jan 1; 32(1):15-27. PMID: 22017519. Abstract
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sørensen P S, Vermersch P, Hamlett A, Viglietta V, Greenberg S, CLARITY Study Group Lancet Neurol. 2011 Apr; 10(4):329-37. PMID: 21397565. Abstract
Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity. Laugel B, Borlat F, Galibert L, Vicari A, Weissert R, Chvatchko Y, Bruniquel D J Neuroimmunol. 2011 Dec 15; 240-241:52-7. PMID: 22035961. Abstract
2-chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells. Singh V, Chittappen K P, Gudi V, Bénardais K, Voss E V, Stangel M Clin Exp Immunol. 2013 Mar 27. PMID: 23607690. Abstract
Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis. Mitosek-Szewczyk K, Tabarkiewicz J, Wilczynska B, Lobejko K, Berbecki J, Nastaj M, Dworzanska E, Kolodziejczyk B, Stelmasiak Z, Rolinski J J Neurol Sci. 2013 Jul 5. PMID: 23835090. Abstract
Cladribine interferes with IL-1β synaptic effects in experimental multiple sclerosis. Musella A, Mandolesi G, Gentile A, Rossi S, Studer V, Motta C, Sepman H, Fresegna D, Haji N, Paolillo A, et al. J Neuroimmunol. 2013 Aug 31. PMID: 24045165. Abstract
Cladribine exerts an immunomodulatory effect on human and murine dendritic cells. Kraus SHP, Luessi F, Trinschek B, Lerch S, Hubo M, Poisa-Beiro L, Paterka M, Jonuleit H, Zipp F, Jolivel V Int Immunopharmacol. 2013 Dec 4. PMID: 24316255. Abstract
Editors' Pick Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Leist TP, Comi G, Cree BAC, Coyle PK, Freedman MS, Hartung H-P, Vermersch P, Casset-Semanaz F, Scaramozza M, oral cladribine for early MS(ORACLE MS) Study Group Lancet Neurol. 2014 Mar; 13(3):257-67. Epub 2014 Feb 04. PMID: 24502830. Abstract
Cladribine Exposure Results in a Sustained Modulation of the Cytokine Response in Human Peripheral Blood Mononuclear Cells. Korsen M, Bragado Alonso S, Peix L, Bröker BM, Dressel A PLoS One. 2015; 10(6):e0129182. Epub 2015 Jun 18. PMID: 26086440. Abstract
Merck KGaA to try again to get approval for MS pill cladribine Burger L, Reuters, 11 Sep 2015 Accessed on 15 Sep 2015 from http://www.reuters.com/article/2015/09/11/us-merck-cladribine-idUSKCN0RB0HF20150911.
Editors' Pick No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner BP, Marta M, Juliusson G, Baker D, Chataway J, Schmierer K Neurol Neuroimmunol Neuroinflamm. 2015 Dec; 2(6):e158. Epub 2015 Oct 01. PMID: 26468472. Abstract
Extension Trial Data Shows Cladribine Benefits Persist in RRMS Patients MPR, 18 Apr 2016 Accessed on 18 Apr 2016 from http://www.empr.com/aan-2016-multiple-sclerosis/extension-trial-data-shows-cladribine-benefits-persist-in-rrms-patients/article/488975/.